Recent developments include Organon's Q1 2026 earnings release showing revenues of $1.46 billion and net income of $146 million, the announcement of the merger agreement with Sun Pharmaceutical for $11.75 billion, and FDA approval extending Nexplanon use to five years. The company completed the divestiture of the Jada System in early 2026.

• Organon reported Q1 2026 revenues of $1.46 billion and net income of $146 million, with basic EPS of $0.56 and diluted EPS of $0.55 [N2][N3].
• The company announced an $11.75 billion merger agreement with Sun Pharmaceutical on April 26, 2026, subject to regulatory and shareholder approvals [N6].
• Organon completed the sale of the Jada System to Laborie Medical Technologies in January 2026 [S1].
• FDA approved a supplemental New Drug Application for Nexplanon extending its duration of use to five years in January 2026 [S1].
• The company continues restructuring initiatives aimed at operational efficiencies, with $95 million in restructuring costs recorded in 2025 [S1].

Organon's diverse portfolio across women's health and general medicines, including growing biosimilars and recently acquired products like Vtama, supports revenue streams. The FDA approval extending Nexplanon use to five years may enhance product attractiveness. The company's active cash flow generation and liquidity position provide financial flexibility. The pending merger with Sun Pharmaceutical could create synergies and expanded market access. Operational restructuring efforts aim to improve efficiency and cost structure. Continued product launches and geographic expansion in biosimilars and established brands may support business growth.

Organon faces significant risks from patent expirations and generic competition impacting key products such as NuvaRing and certain biosimilars. The company recorded a substantial goodwill impairment in 2025 reflecting challenges in U.S. patent-protected products and macroeconomic uncertainties. The merger with Sun Pharmaceutical is subject to regulatory and shareholder approvals with risks of delay or termination, which could disrupt operations and liquidity. The company has substantial debt maturing in 2028, with refinancing risks if the merger does not close. Competitive pressures, pricing challenges, and potential litigation related to the merger add to business risks. Operational restructuring and cost reduction efforts may not fully offset revenue pressures.

Organon's moat is based on its specialized focus on women's health products, including long-acting contraceptives like Nexplanon, and a broad portfolio of biosimilars and established brands with global reach. The company's manufacturing footprint across multiple countries supports supply chain resilience. Its portfolio includes products with regulatory approvals and market presence in over 140 countries, providing geographic diversification. The company's ability to commercialize biosimilars and maintain established brands in competitive markets contributes to its competitive positioning. However, the presence of generic competition and patent expirations pose ongoing challenges to sustaining market share and pricing power.

• Merger Completion Risk: The merger with Sun Pharmaceutical is subject to customary closing conditions including regulatory approvals and shareholder vote. Failure to satisfy these conditions could delay or prevent completion, adversely affecting business operations, stock price, and liquidity [S2].
• Debt Refinancing Risk: Organon has $3.6 billion of debt maturing in 2028. If the merger does not close, the company may face challenges refinancing this debt, potentially requiring access to credit markets or equity financing under less favorable terms [S2].
• Competitive and Market Risks: The company faces ongoing generic competition and pricing pressures on key products, including contraceptives and biosimilars, which impact revenue and profitability [S1].
• Goodwill Impairment and Financial Performance: A $301 million goodwill impairment was recorded in 2025 due to lower-than-expected financial performance and macroeconomic uncertainties, indicating sensitivity of the U.S. reporting unit to adverse conditions [S1].
• Operational Disruption and Employee Retention: The merger process and restructuring initiatives may divert management attention and create uncertainty among employees, potentially affecting business execution and retention [S2].

• Organon & Co. is a global healthcare company focused on women's health and general medicines, with a portfolio of over 70 products sold in more than 140 countries and territories [S1].
• The company operates six manufacturing facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom [S1].
• Organon's women's health portfolio includes prescription contraceptives such as Nexplanon (etonogestrel implant) and NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), and fertility treatments like Follistim AQ (follitropin beta injection) [S1].
• The Jada System, a device for postpartum uterine bleeding control, was divested to Laborie Medical Technologies in January 2026 [S1].
• The general medicines portfolio includes biosimilars and established brands across immunology, oncology, cardiovascular, respiratory, dermatology, and non-opioid pain management [S1].
• Key biosimilars include Renflexis, Hadlima, Ontruzant, Brenzys, and recently launched Bildyos and Bilprevda in the U.S. [S1].
• Hadlima sales increased 60% in 2025 due to ramp-up since its U.S. launch in July 2023 [S1].
• Established brands include Atozet, Zetia/Vytorin, Cozaar/Hyzaar, Singulair, Nasonex, Dulera, Arcoxia, Vtama, and Emgality [S1].
• Sales trends in 2025 showed declines in some established brands due to loss of exclusivity and generic competition, while some products like Emgality and Vtama showed growth due to acquisitions and new indications [S1].
• The company recognized a goodwill impairment of $301 million in 2025 related to U.S. patent-protected products due to lower-than-expected financial performance and macroeconomic uncertainties [S1].
• Restructuring costs of $95 million in 2025 were primarily related to headcount reductions aimed at operational efficiencies [S1].
• Interest expense decreased 3% in 2025 due to refinancing and debt repurchases [S1].
• Organon reported revenues of $1.46 billion and net income of $146 million for the quarter ended March 31, 2026, with basic EPS of $0.56 and diluted EPS of $0.55 [S2].
• Liquidity as of March 31, 2026, included cash and equivalents of $1.116 billion, current assets of $4.932 billion, current liabilities of $2.5 billion, resulting in a current ratio of 1.97 and a cash ratio of 0.45 [S2].
• The company has accounts receivable factoring agreements reducing receivables by $217 million as of December 31, 2025 [S1].
• Organon has contractual obligations including $2.2 billion in potential milestone payments and $1.1 billion in purchase obligations extending through 2033 [S1].
• The company pays dividends, with a quarterly dividend declared in February 2026 of $0.02 per share [S1].
• Organon entered into a merger agreement with Sun Pharmaceutical on April 26, 2026, for an $11.75 billion acquisition, subject to customary closing conditions including regulatory approvals and shareholder approval [N6][S2].
• The merger completion is subject to risks including regulatory approvals, potential termination fees, and possible disruption to business operations and employee retention [S2].
• If the merger does not close, Organon may face liquidity challenges related to repayment or refinancing of $3.6 billion of debt maturing in 2028, requiring access to credit markets or equity financing [S2].
• The company generates positive cash flow from operations, with $700 million net cash provided in 2025, but net cash used in financing activities was $561 million due to debt repurchases and dividend payments [S1][S2].
• Revenue recognition involves estimates for discounts, rebates, chargebacks, and returns, with revenues recorded net of these provisions [S1].
• Major customers include drug wholesalers, retailers, hospitals, government agencies, managed healthcare providers, and pharmacy benefit managers, with largest accounts receivable balances from McKesson Corporation and Cencora, Inc. [S1][S2].
• The company faces competitive pressures and generic competition impacting sales of certain products, notably NuvaRing and some biosimilars [S1].
• Organon maintains stock-based compensation plans including stock options, restricted stock units, and performance share units with vesting over three years [S1].
• The company has pension plans primarily in Switzerland, Belgium, South Korea, Germany, and Italy, with net periodic benefit costs disclosed [S1].
• Organon has a returns policy allowing product returns within specified periods before and after expiration, with provisions estimated based on historical experience [S1].
• The company’s effective income tax rate was 56.0% in 2025, influenced by goodwill impairment and other tax factors [S1].
• Organon’s revenues for the year ended December 31, 2025, were $6.216 billion, with a gross profit of $3.313 billion and net income of $187 million [S1].